Catherine Skari

NEW FACTSHEET | The Advanced Therapy Medicinal Products (ATMPs) Labyrinth

Featuring comprehensive information on: The Regulation of ATMPs in the EU List of gene-based products approved by the EMA/FDA Challenges…

Read More »

POSITION PAPER | The Views of TIF on Advanced Therapy Medicinal Products (ATMPs)

The Thalassaemia International Federation (TIF) is pleased to share its newly published Position Paper, titled “Advanced Therapy Medicinal Products (ATMPs).”…

Read More »

INFOGRAPHICS | Mapping Blood Use in Patients with Thalassaemia Across the EU

Have You Ever Wondered How Much Blood is Consumed by Patients with Thalassaemia in EU Countries? To answer this question,…

Read More »

EXCLUSIVE WEBINAR | Iron Load and the Importance of Reliable Monitoring in Haemoglobin Disorders

📌 Webinar Title: Iron Load and the Importance of Reliable Monitoring in Haemoglobin Disorders – The Transfusion Dependent Thalassaemia (TDT)…

Read More »

EDUCATIONAL WEBINAR FOR PATIENTS ON IRON OVERLOAD AND MONITORING | 21 November 2024

📌 Webinar Title: Webinar for Patients on Iron Overload and Iron Monitoring  📌 Date & Time: Thursday, November 21, 13:00…

Read More »

SICKLE CELL DISEASE | FDA Grants Orphan Drug Designation to AND017

Announced by KIND Pharmaceuticals on October 25, 2024, ODD is granted to a drug or biological product to prevent, diagnose,…

Read More »

TIF STUDY | Desferioxamine Usage Survey

Desferioxamine is crucial in managing iron overload for many patients with thalassaemia and related blood conditions. Recently, the Thalassaemia International…

Read More »

COUNTRIES | The Maldives Launches Thalassaemia-Specialized Hospital and 10-Year Strategic Disease Plan

Read More »

Splenectomy as Treatment for Primary Warm Autoimmune Hemolytic Anemia (wAIHA)

Warm Autoimmune Hemolytic Anemia (wAIHA) occurs when the body’s immune system mistakenly produces antibodies that attack and destroy its own…

Read More »

WHAT YOU NEED TO KNOW | EMA Recommends Suspension of Pfizer’s Sickle Cell Disease Drug Oxbryta

Oxbryta, which was designed to treat sickle cell disease, has been a crucial medication for patients with mild-to-moderate symptoms. Approved…

Read More »